The thrifty phenotype hypothesis revisited by A. A. Vaag et al.
THEN AND NOW
The thrifty phenotype hypothesis revisited
A. A. Vaag & L. G. Grunnet & G. P. Arora & C. Brøns
Received: 20 March 2012 /Accepted: 3 April 2012 /Published online: 30 May 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Twenty years ago, Hales and Barker along with
their co-workers published some of their pioneering papers
proposing the ‘thrifty phenotype hypothesis’ in Diabetologia
(4;35:595–601 and 3;36:62–67). Their postulate that fetal
programming could represent an important player in the origin
of type 2 diabetes, the metabolic syndrome and cardiovascular
disease (CVD) was met with great scepticism.
More recently, their observations have been confirmed
and expanded in many epidemiological and animal experi-
mental studies, and human integrative physiological studies
have provided insights into some of the underlying molec-
ular mechanisms. Type 2 diabetes is a multiple-organ dis-
ease, and developmental programming, with its idea of
organ plasticity, is a plausible hypothesis for a common
basis for the widespread organ dysfunctions in type 2 dia-
betes and the metabolic syndrome. Only two among the 45
known type 2 diabetes susceptibility genes are associated
with low birthweight, indicating that the association be-
tween low birthweight and type 2 diabetes is mainly non-
genetic. Prevention programmes targeting adult lifestyle fac-
tors seems unable to stop the global propagation of type 2
diabetes, and intensive glucose control is inadequate to reduce
the excess CVD mortality in type 2 diabetic patients. Today,
the thrifty phenotype hypothesis has been established as a
promising conceptual framework for a more sustainable inter-
generational prevention of type 2 diabetes.
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Research into insulin resistance, type 2 diabetes and the
metabolic syndrome took off in the 1960s after the first
human plasma insulin assays demonstrated that the majority
of cases of late-onset diabetes could not be explained suffi-
ciently by lack of insulin [1]. Twin studies from the 1980s
suggested an almost exclusive role of genetics in type 2
diabetes, with nearly 100% concordance rates among genet-
ically identical monozygotic twins [2]. The studies of Hales
and Barker et al. [3, 4], published in Diabetologia in the
early 1990s, were therefore highly provocative to the diabe-
tes research community, postulating that not only type 2
diabetes, but also the key components of the metabolic
syndrome, representing well-established cardiovascular dis-
ease (CVD) risk factors, seemed to have at least parts of
their origin in early life. The notion that factors operating
early in life influence the risk of type 2 diabetes and CVD
decades later was originally devised by the Norwegian
epidemiologist Anders Forsdahl in the 1970s [5]. Neverthe-
less, the undisputable achievement of Hales and Barker was
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that, in an unselected population sample from Hertfordshire,
UK, they proved a direct link between low weight at birth
and increased risks of developing type 2 diabetes, hyperten-
sion, elevated triacylglycerols and insulin resistance later in
life [3, 6]. Thus, the paradigm-shifting potential of the
studies was not only the idea of a role of fetal program-
ming in itself but, equally as important, the notion that
fetal programming could represent a significant player in
the origin of type 2 diabetes, the metabolic syndrome and
CVD.
Criticism of the studies of Hales and Barker included the
use of changing definitions of markers of growth in early
life and underdevelopment in different studies, such as
birthweight versus ponderal index with respect to exposure,
and different phenotypes such as type 2 diabetes, the meta-
bolic syndrome and insulin resistance with respect to out-
come. As disbelievers ignored the provocative ideas,
supporters gathered in societies somewhat isolated from
the general community of diabetes research. This polarisa-
tion might have impeded the speed at which the ideas of
fetal programming were widely accepted. For example,
technological developments within molecular biology, such
as the genome-wide association platform, were more rapidly
adopted by researchers in the field of type 2 diabetes genet-
ics, which facilitated the identification of a fascinating sce-
nario of distinct molecular causes and disease mechanisms
of type 2 diabetes [7]. These important achievements must
be considered in the context of the fact that, although more
than 45 genes are currently documented to be associated
with type 2 diabetes, these quantitatively account for only
around 10% of the primary constitutional origin of type 2
diabetes [7]. Accordingly, the major primary aetiological fac-
tors involved in type 2 diabetes remain unexplained, which
leaves substantial potential for early life determinants to be
central in the aetiology of type 2 diabetes.
Alongside the diverse beliefs and conceptions regarding
the aetiology of type 2 diabetes and the metabolic syndrome,
there was a strong polarisation of views in the 1980s and
1990s concerning the roles of muscle insulin resistance,
defective pancreatic insulin secretion and elevated hepatic
glucose production in the pathophysiology of type 2 diabe-
tes. This debate has now been settled by a uniform agree-
ment that glucose intolerance, ranging from the prediabetic
states of impaired fasting glucose and impaired glucose
tolerance to overt type 2 diabetes, constitutes heterogeneous
dysmetabolic states, involving the dysfunction of multiple
organs, including the liver, muscle, pancreas, adipose tissue,
gut, kidney and brain [8]. It is of interest that the concept of
fetal programming, with its ideas of organ plasticity [4],
may represent the most plausible hypothesis of a common
ground for the underlying aetiology and molecular mecha-
nisms of type 2 diabetes. Thus, the multiple organ dysfunctions
in type 2 diabetes, changing with time and age, and differing in
magnitude between type 2 diabetic patients within and be-
tween societies, require a comprehensive conceptual frame-
work such as developmental programming, as illustrated in
Fig. 1. Type 2 diabetes genes have appeared to be more
selective in their influence on organ dysfunctions, with defec-
tive pancreatic insulin secretion being the most important [7].
In contrast, despite their initial hypothesis of fetal program-
ming of type 2 diabetes being associated with impaired insulin
secretion [4], Hales and Barker and colleagues were the first to
document the association between low birthweight and insulin
resistance in humans [6]. The importance of this finding is
underscored by our knowledge that insulin resistance is a very
prominent and early feature of themetabolic syndrome and has
consistently been associated with fetal programming in
humans, regardless of whether the exposure is low birthweight,
prematurity independent of low birthweight, gestational
diabetes mellitus (GDM) or twin/zygosity status [9–11].
Regarding the definition of the metabolic syndrome,
central points in the discussion of its raison d´être over
recent years have been whether it is a real disease entity of
clinical relevance, if insulin resistance is the main common
denominator or cause, if it explains the risk of CVD beyond
the contributions of each of the individual components, and
whether the clustering of the proposed components of the
metabolic syndrome may be an artefact when observed from
a stringent epidemiological perspective. What has not been
sufficiently emphasised in this debate is that the thrifty
phenotype hypothesis, formulated with great visionary pre-
cision by Hales and Barker et al [3], represents the most
plausible explanation of the origin of all of the components
of the metabolic syndrome.
The idea of an adverse fetal environment rather than
genetic determinants defining the origin of type 2 diabetes,
the metabolic syndrome and CVD was supported by twin
studies reporting lower birthweights among monozygotic
twins with type 2 diabetes compared with their genetically
identical but non-diabetic co-twins [12]. Subsequent twin
studies documented that both defective insulin secretion and
insulin resistance were associated with low birthweight in a
complex non-genetic and age-dependent manner [11]. The
age dependency may in this context represent an important
issue to explain the highly age-dependent states of type 2
diabetes and the metabolic syndrome, as well as CVD.
While the concordance estimates from population-based
twin studies questioned the notion of a major genetic com-
ponent in type 2 diabetes [13], perhaps the most significant
lesson from twin studies was the finding that zygosity—and
thus twin status—may influence insulin secretion and insu-
lin action [11]. The extent to which twins develop type 2
diabetes in a differential age-dependent manner compared
with singletons is currently unresolved [13, 14], but the
finding that twins have a risk of type 2 diabetes that is
similar to a singleton with a lower birthweight is consistent
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with the notion that twins may differ from singletons with
respect to risk of type 2 diabetes. Thus, the thrifty phenotype
hypothesis has challenged the role of the classic twin model
in the assessment of genetic versus non-genetic risk of
metabolic and CVD diseases, emphasising the enormous
impact of the hypothesis.
Despite low birthweight being a crude marker of an
adverse intrauterine environment, it has, with remarkable
consistency, been associated with risk of type 2 diabetes as
well as impaired insulin secretion and insulin resistance in
multiple studies, including population-based epidemiologi-
cal investigations [10]. In addition, studies of the identified
genetic type 2 diabetes markers have confirmed the notion
that the association is predominantly non-genetic. While
prematurity is associated with risk of type 2 diabetes inde-
pendently of birthweight [10], studies of third trimester fetal
growth rate pointed towards effects prior to or after the third
trimester (i.e. all periods except the third trimester) being the
most important periods during development relevant to
programming of components of the metabolic syndrome
[15].
Animal studies have provided substantial ‘proof of
concept’ for associations of global as well as protein under-
nutrition during pregnancy with glucose intolerance and phys-
iological and metabolic defects relevant to type 2 diabetes in
their offspring [16]. Importantly, comparative studies of low
birthweight in humans and protein-undernourished rats
in utero identified strikingly similar changes in the expression
of key insulin signalling proteins and of the glucose transport-
er GLUT4 in both skeletal muscle and adipose tissue [17]. The
increasing awareness of a prime role of epigenetics, including
DNA methylations and histone modifications, as well as
regulatory microRNAs, has provided ideas and novel tools
to look for the mechanisms that underlie the developmental
programming of organ defects relevant to insulin resistance
and type 2 diabetes, forecasting groundbreaking discoveries
within the years to come. Prominent examples of recent dis-
coveries in the area include transcriptional regulation by pro-
moter DNA methylation and histone modifications of the key
pancreatic proliferation and transcription factor Pdx1 by fetal
undernutrition [16], and the discovery of increased expression
of miR-483-3p in subcutaneous adipose tissue from humans
with a low birthweight and from rats that were protein under-
nourished in utero, conferring an increased risk of lipotoxicity
with its detrimental effects on the functioning of organs asso-
ciated with type 2 diabetes [18].
The extent to which the global diabetes epidemic may be
driven by a mismatch between being born with a low birth-
weight and the fast propagation of overnutrition and phys-
ical inactivity seen over recent years in developing countries
needs to be determined to provide a focus for efforts to
prevent metabolic diseases. GDM may be considered an
early manifestation of type 2 diabetes that is unmasked by
pregnancy-induced insulin resistance, and studies in both
animals and humans have indicated that exposure to an
adverse fetal environment is a significant risk factor for
GDM per se [19]. Besides compelling evidence of intergen-
erational transmission of type 2 diabetes and the metabolic
syndrome via low birthweight and GDM, recognition of this
has provided support for universal GDM screening, and for
pregnancy being a window of opportunity to prevent type 2

















Fig. 1 The developmental
origin of type 2 diabetes
provides a conceptual
framework to explain the
multiple organ defects
in type 2 diabetes
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importance of earlier and more effective prevention of
type 2 diabetes and the increased CVD mortality associated
with this condition is underscored by the modest effects of
early detection (and implementation of treatment) by screen-
ing for type 2 diabetes in the general population on type 2
diabetes-associated mortality [20], as well as the absence of
any significant effect of intensive as opposed to convention-
al glucose control on CVD mortality in patients with overt
type 2 diabetes [21]. To understand the full potential of the
thrifty phenotype hypothesis as a platform to implement
primary prevention of type 2 diabetes there is an urgent
need to determine the extent to which developmental
programming influences the development of type 2 diabetes
in different populations and to understand the long-term
effects of exposures during pregnancy and the distinct mo-
lecular mechanisms involved.
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